Part 4 - Preparation of microgel co-loaded with nuciferine and epigallocatechin-3-gallate for the regulation of lipid metabolism

References

  • 1.Guo F, Yang X, Li X, Feng R, Guan C, Wang Y, et al. Nuciferine prevents hepatic steatosis and injury induced by a high-fat diet in hamsters. PLoS One. (2013) 8:e63770. 10.1371/journal.pone.0063770 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Yan W, Xia J, Xu J, Chen L, Yang Y, Wu J, et al. Nuciferine, an active ingredient derived from lotus leaf, lights up the way for the potential treatment of obesity and obesity-related diseases. Pharmacol Res. (2022) 175:106002. 10.1016/j.phrs.2021.106002 [DOI] [PubMed] [Google Scholar]
  • 3.Xu H, Wang L, Yan K, Zhu H, Pan H, Yang H, et al. Nuciferine inhibited the differentiation and lipid accumulation of 3T3-L1 preadipocytes by regulating the expression of lipogenic genes and adipokines. Front Pharmacol. (2021) 12:632236. 10.3389/fphar.2021.632236 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zhang G, Zhang J. Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats. Drug Des Devel Ther. (2018) 12:2509–18. 10.2147/DDDT.S172919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wang Y, Yao W, Li B, Qian S, Wei B, Gong S, et al. Nuciferine modulates the gut microbiota and prevents obesity in high-fat diet-fed rats. Exp Mol Med. (2020) 52:1959–75. 10.1038/s12276-020-00534-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Tang G, Xu Y, Zhang C, Wang N, Li H, Feng Y. Green tea, and epigallocatechin gallate (EGCG) for the management of nonalcoholic fatty liver diseases (NAFLD): insights into the role of oxidative stress and antioxidant mechanism. Antioxidants. (2021) 10:1076. 10.3390/antiox10071076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Chen C, Liu Q, Liu L, Hu Y, Feng Q. Potential biological effects of (–)-epigallocatechin-3-gallate on the treatment of nonalcoholic fatty liver disease. Mol Nutr Food Res. (2018) 62:1700483. 10.1002/mnfr.201700483 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan C, et al. Drugging DNA repair to target T-all cells. Leuk Lymphoma. (2018) 59:1746–9. 10.1080/10428194.2017.1397662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sun X, Wang H, Li S, Song C, Zhang S, Ren J, et al. Maillard-type protein-polysaccharide conjugates and electrostatic protein-polysaccharide complexes as delivery vehicles for food bioactive ingredients: formation. types, and applications. Gels. (2022) 8:135. 10.3390/gels8020135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Huang J, Xie W, Liu L, Song Y, Pan F, Bai H, et al. Nanostructured lipid carriers in alginate microgels for the delivery of astaxanthin. Eur J Lipid Sci Technol. (2021) 123:2000191. 10.1002/ejlt.202000191 [DOI] [Google Scholar]
  • 11.Feng R, Wang L, Zhou P, Luo Z, Li X, Gao L. Development of the pH responsive chitosan-alginate based microgel for encapsulation of jughans regia L. polyphenols under simulated gastrointestinal digestion in vitro. Carbohydr Polym. (2020) 250:116917. 10.1016/j.carbpol.2020.116917 [DOI] [PubMed] [Google Scholar]
  • 12.Nguyen T, Huang L, Gauthier M, Yang G, Wang Q. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine. (2016) 11:1169–85. 10.2217/nnm.16.9 [DOI] [PubMed] [Google Scholar]
  • 13.Poznyak A, Grechko A, Poggio P, Myasoedova V, Alfieri V, Orekhov A. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. (2020) 21:1835. 10.3390/ijms21051835 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta. (2015) 1852:1765–78. 10.1016/j.bbadis.2015.05.015 [DOI] [PubMed] [Google Scholar]
  • 15.Gjorgjieva M, Sobolewski C, Dolicka D, Correia de Sousa M, Foti M. miRNAs and NAFLD: from pathophysiology to therapy. Gut. (2019) 68:2065–79. 10.1136/gutjnl-2018-318146 [DOI] [PubMed] [Google Scholar]
  • 16.Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom A, Verheij J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. (2020) 17:279–97. 10.1038/s41575-020-0269-9 [DOI] [PubMed] [Google Scholar]
  • 17.Shah S, Dhawan V, Holm R, Nagarsenker M, Perrie Y. Liposomes: advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. (2020) 154-155:102–22. 10.1016/j.addr.2020.07.002 [DOI] [PubMed] [Google Scholar]
  • 18.Zhang L, Zhang Z, Chen Y, Ma X, Xia M. Chitosan and procyanidin composite films with high antioxidant activity and pH responsivity for cheese packaging. Food Chem. (2021) 338:128013. 10.1016/j.foodchem.2020.128013 [DOI] [PubMed] [Google Scholar]
  • 19.Zou T, Percival S, Cheng Q, Li Z, Rowe C, Gu L. Preparation, characterization, and induction of cell apoptosis of cocoa procyanidins-gelatin-chitosan nanoparticles. Eur J Pharm Biopharm. (2012) 82:36–42. 10.1016/j.ejpb.2012.05.006 [DOI] [PubMed] [Google Scholar]
  • 20.Richa, Roy Choudhury A. pH mediated rheological modulation of chitosan hydrogels. Int J Biol Macromol. (2020) 156:591–7. 10.1016/j.ijbiomac.2020.04.049 [DOI] [PubMed] [Google Scholar]
  • 21.Wang Q, Wei H, Deng C, Xie C, Huang M, Zheng F. Improving stability and accessibility of quercetin in olive oil-in-soy protein isolate/pectin stabilized O/W emulsion. Foods. (2020) 9:123. 10.3390/foods9020123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, et al. Epigallocatechin-3-gallate dampens non-alcoholic fatty liver by modulating liver function, lipid profile and macrophage polarization. Nutrients. (2021) 13:599. 10.3390/nu13020599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Cui H, Li Y, Cao M, Liao J, Liu X, Miao J, et al. Untargeted metabolomic analysis of the effects and mechanism of nuciferine treatment on rats with nonalcoholic fatty liver disease. Front Pharmacol. (2020) 11:858. 10.3389/fphar.2020.00858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Arbelaiz A, Azkargorta M, Krawczyk M, Santos-Laso A, Lapitz A, Perugorria M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. (2017) 66:1125–43. 10.1002/hep.29291 [DOI] [PubMed] [Google Scholar]
  • 25.Théry C, Witwer K, Aikawa E, Alcaraz M, Anderson J, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. (2018) 7:1535750. 10.1080/20013078.2018.1535750 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sun H, Meng Q, Shi C, Yang H, Li X, Wu S, et al. Hypoxia-inducible exosomes facilitate liver-tropic premetastatic niche in colorectal cancer. Hepatology. (2021) 74:2633–51. 10.1002/hep.32009 [DOI] [PubMed] [Google Scholar]
  • 27.Caporaso J, Kuczynski J, Stombaugh J, Bittinger K, Bushman F, Costello E, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. (2010) 7:335–6. 10.1038/nmeth.f.303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett W, et al. Metagenomic biomarker discovery and explanation. Genome Biol. (2011) 12:R60. 10.1186/gb-2011-12-6-r60 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Fang K, Wu F, Chen G, Dong H, Li J, Zhao Y, et al. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells. BMC Complement Altern Med. (2019) 19:255. 10.1186/s12906-019-2671-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bougarne N, Weyers B, Desmet S, Deckers J, Ray D, Staels B, et al. Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. (2018) 39:760–802. 10.1210/er.2018-00064 [DOI] [PubMed] [Google Scholar]
  • 31.Li T, Hu S, Pang X, Wang J, Yin J, Li F, et al. The marine-derived furanone reduces intracellular lipid accumulation in vitro by targeting LXRα and PPARα. J Cell Mol Med. (2020) 24:3384–98. 10.1111/jcmm.15012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Hao J, Wang J, Guo H, Zhao Y, Sun H, Li Y, et al. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. (2020) 11:4765. 10.1038/s41467-020-18565-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cifarelli V, Abumrad N. Intestinal CD36 and other key proteins of lipid utilization: role in absorption and gut homeostasis. Compr Physiol. (2018) 8:493–507. 10.1002/cphy.c170026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lu J, Fang B, Huang Y, Tao S, Sun B, Guan S, et al. Epigallocatechin-3-gallate protects against 1,3-dichloro-2-propanol-induced lipid accumulation in C57BL/6J mice. Life Sci. (2018) 209:324–31. 10.1016/j.lfs.2018.08.007 [DOI] [PubMed] [Google Scholar]
  • 35.Zhang Q, Ma X, Dong M, Tan J, Zhang J, Zhuang L, et al. MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in huh-7 cell line. Lipids Health Dis. (2020) 19:76. 10.1186/s12944-020-01261-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Yin J, Li Y, Han H, Chen S, Gao J, Liu G, et al. Melatonin reprogramming of gut microbiota improves lipid dysmetabolism in high-fat diet-fed mice. J Pineal Res. (2018) 65:e12524. 10.1111/jpi.12524 [DOI] [PubMed] [Google Scholar]
  • 37.Dimova L, Zlatkov N, Verkade H, Uhlin B, Tietge U. High-cholesterol diet does not alter gut microbiota composition in mice. Nutr Metab. (2017) 14:15. 10.1186/s12986-017-0170-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wang B, Kong Q, Li X, Zhao J, Zhang H, Chen W, et al. A high-fat diet increases gut microbiota biodiversity and energy expenditure due to nutrient difference. Nutrients. (2020) 12:10. 10.3390/nu12103197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Canfora E, Jocken J, Blaak E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. (2015) 11:577–91. 10.1038/nrendo.2015.128 [DOI] [PubMed] [Google Scholar]
  • 40.Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. (2015) 5:14405. 10.1038/srep14405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wu M, Yang S, Wang S, Cao Y, Zhao R, Li X, et al. Effect of berberine on atherosclerosis and gut microbiota modulation and their correlation in high-fat diet-fed apoe-/- mice. Front Pharmacol. (2020) 11:223. 10.3389/fphar.2020.00223 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ye X, Liu Y, Hu J, Gao Y, Ma Y, Wen D. Chlorogenic acid-induced gut microbiota improves metabolic endotoxemia. Front Endocrinol. (2021) 12:762691. 10.3389/fendo.2021.762691 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1

Morphological observation of liver.

Click here for additional data file. (1.6MB, TIF)

Data Availability Statement

The original contributions presented in this study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA882230

Back to blog